acs 2
 
bar

program

slides

  test

syllabus
bar
 
 

Critical Challenges in
Cardiovascular Medicine

Advancing Management of Acute Coronary Syndromes (ACS)—Establishing Interventional Cardiology & Emergency Medicine Therapeutic Teams
New York, NY

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This symposium is designed for interventional cardiologists, cardiologists, emergency physicians, program directors, and other healthcare providers caring for patients with acute cardiovascular disease.

Registration:

Enrollment for this webcast is complimentary, and clinicians are invited to attend this CME-certified symposium and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

rocheSupported by an independent educational grant from The Medicines Company, Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

Gregg W. Stone, MD, FACC
Grant/Research Support: The Medicines Co.
Consultant: The Medicines Co.
Frederick Feit, MD, FACC
Consultant: The Medicines Co.
Major Shareholder: Johnson & Johnson, Millennium Pharmaceuticals, The Medicines Co.
Charles V. Pollack, MD, FACEP

Grant/Research Support: GlaxoSmithKline
Consultant: The Medicines Co., Schering-Plough, Sanofi-Aventis, BMS, Genentech
Speaker’s Bureau: Schering-Plough, Sanofi-Aventis, BMS, Genentech

Program Faculty:

Gregg W. Stone, MD, FACC
Professor of Medicine
Columbia University
Director of Cardiovascular Research and Education
Center for Interventional Vascular Therapy
Columbia University Medical Center
Chairman, The Cardiovascular Research Foundation
New York, NY
Frederick Feit, MD, FACC
Associate Professor of Medicine
New York University School of Medicine
Director of Interventional Cardiology
New York University Medical Center
New York, NY
Charles V. Pollack, MD, FACEP, FAAEM

Chairman, Department of Emergency Medicine
Pennsylvania Hospital
Professor of Emergency Medicine
University of Pennsylvania Medical School
Philadelphia, PA

Educational Objectives:

  • As a result of this session, cardiologists and emergency physicians will be able to assess and implement optimal antithrombotic strategies for patients with acute coronary syndromes (ACS).
  • As a result of this session, attendees will understand impact of specific pharmacologic agents on outcomes, including ischemic endpoints, bleeding, and mortality for patients with ACS.
  • As a result of this session, attendees are able to discuss the impact that new trials are likely to have on future management of patients with ACS.
  • As a result of this session, ED physicians and cardiologists will learn to apply AHA/ACC, ACCP, and other national guidelines in order to optimize therapy ACS.

Disclaimer:

Copyright © 2007 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides

  test

syllabus
bar

YES, I have read the CME information statement

Copyright (c) 2007 All rights reserved


 
6

 

 

 

 

Key Program Topics Include:
Abciximab
ACEI
ACS
ACS Management
ACUITY
ACUITY Timing trial
Acute coronary syndromes
AHA/ACC guidelines
Angiography
anticoagulant
Anti-platelet therapy
Antithrombotic
ARB
aspirin
Bivalirudin
Bleeding
bleeding
CABG
cath lab
catheterization







Clopidogrel
correct negative impact of bleeding?
CRUSADE
CRUSADE
CURE
ECG
EDICT
EDICT for ACS
Emergency
enoxaparin
EPIC EQOL Study
Eptifibatide
fondaparinux
FRISC II
GP IIb/IIIa
GUSTO
hemorrhage
heparin
Hgb decrease
INTERACT

invasive
ISAR-REACT 2
ischemia
ischemic
MI
Myocardial infarction
Myoglobin
Net Clinical Outcome Composite
Net Clinical Outcome Composite Endpoint
Net Clinical Outcomes
non–ST segment elevation
NSTE-ACS
NSTEMI
OASIS 5
PCI
Percutaneous coronary intervention
PF-4
RBC Transfusions
receptor antagonist
refractory ischemia
revascularization
STEMI
SYNERGY
TACTICS
TACTICS/TIMI 18
Thrombin
thrombin-mediated platelet activation
thrombus
TIMI
Timing Trial
tirofiban
transfusions
Troponin
troponin (+)
troponin-positive
UA
UFH
UFH/LMWH
unfractionated heparin
Unstable angina
upstream